Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Monopar Therapeutics Inc. - Common Stock (NQ:MNPR)

57.24 -4.49 (-7.27%)
Streaming Delayed Price Updated: 12:14 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Monopar Therapeutics Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Announces 1-for-5 Reverse Stock Split
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar and NorthStar Amend & Extend Collaboration
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces CFO Succession
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments
MNPR-101 Radiopharma Program to Enter First-in-Human Studies Potentially As Early As December of This Year Camsirubicin Phase 1b Trial Efficacy and Safety Data Highlighted at the 2023 CTOS Annual... 
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Provides Encouraging Camsirubicin Clinical Data Update
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar to Participate in the Radiopharma Forum by the Lake 2023
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments
Camsirubicin Phase 1b Dose­Escalation Trial Enrolling 5th Dose­Level Cohort (650 mg/m2) MNPR-101 RIT Shows Promising Imaging and Therapeutic Preclinical Study Results 
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar to Present at the Jefferies Radiopharma Innovation Summit
From Monopar Therapeutics Inc.
Via GlobeNewswire
News headline image
Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis
From Monopar Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.